NEWS!
Progressive Care Issues Shareholder Update
MIAMI, FL--(Marketwired - June 17, 2016) - Progressive Care Inc. (OTC PINK: RXMD), through its subsidiary Pharmco LLC, a South Florida health services organization and provider of prescription pharmaceuticals specializing in health practice risk management, compounded medications, the sale of anti-retroviral medications and related medication therapy management, and the supply of prescription medications to long term care facilities, issues follow up to shareholders on the status of potential acquisitions.
Dear Valued Shareholders,
On June 15, 2016 the Progressive Care issued a press release updating the public on the sales for May 2016 and status of proposed acquisition targets in the home health care space.
First, we would like to clarify that the decision to suspend our pursuit of home health care agencies as potential acquisition targets is in no way connected to the core business of PharmCo, LLC or its expansion into other state markets. PharmCo is continuing to file applications in states across the country to extend the reach of our custom compound business line.
Progressive Care was in the LOI/due diligence stage with a potential acquisition target in the home health care industry. Upon receiving the update on the new regulations and pre-claim authorization procedures for the industry, the Company decided to terminate the LOI until the management team could ascertain the ramifications of the new protocols on the home health care industry. As was mentioned in the press release issued on June 15th, the Company believes that the new CMS procedures will decrease the number of approved claims for home health care and increase the cost of reviewing, processing, and adjudicating such claims.
We are fortunate that we received the new information from CMS at this stage of the acquisition process. It allowed us to terminate the LOI without any penalties or break-up fees in addition to preventing us from closing on an ultimately costly acquisition. The early stage termination also had the added benefit of allowing the company to continue its conversations with the sellers of these targets about potential acquisitions of companies in other health care arenas.
We want to assure the shareholders that the goals of the company remain unchanged. The Company still plans to identify and evaluate potential acquisition targets both within and outside the pharmacy industry. The Company continues to be on track to reach its annual sales and earnings goals as well as its expansion objectives.
Sincerely,
S. Parikh Mars
CEO
Progressive Care Inc.
Progressive Care Issues Shareholder Update
MIAMI, FL--(Marketwired - June 17, 2016) - Progressive Care Inc. (OTC PINK: RXMD), through its subsidiary Pharmco LLC, a South Florida health services organization and provider of prescription pharmaceuticals specializing in health practice risk management, compounded medications, the sale of anti-retroviral medications and related medication therapy management, and the supply of prescription medications to long term care facilities, issues follow up to shareholders on the status of potential acquisitions.
Dear Valued Shareholders,
On June 15, 2016 the Progressive Care issued a press release updating the public on the sales for May 2016 and status of proposed acquisition targets in the home health care space.
First, we would like to clarify that the decision to suspend our pursuit of home health care agencies as potential acquisition targets is in no way connected to the core business of PharmCo, LLC or its expansion into other state markets. PharmCo is continuing to file applications in states across the country to extend the reach of our custom compound business line.
Progressive Care was in the LOI/due diligence stage with a potential acquisition target in the home health care industry. Upon receiving the update on the new regulations and pre-claim authorization procedures for the industry, the Company decided to terminate the LOI until the management team could ascertain the ramifications of the new protocols on the home health care industry. As was mentioned in the press release issued on June 15th, the Company believes that the new CMS procedures will decrease the number of approved claims for home health care and increase the cost of reviewing, processing, and adjudicating such claims.
We are fortunate that we received the new information from CMS at this stage of the acquisition process. It allowed us to terminate the LOI without any penalties or break-up fees in addition to preventing us from closing on an ultimately costly acquisition. The early stage termination also had the added benefit of allowing the company to continue its conversations with the sellers of these targets about potential acquisitions of companies in other health care arenas.
We want to assure the shareholders that the goals of the company remain unchanged. The Company still plans to identify and evaluate potential acquisition targets both within and outside the pharmacy industry. The Company continues to be on track to reach its annual sales and earnings goals as well as its expansion objectives.
Sincerely,
S. Parikh Mars
CEO
Progressive Care Inc.
